Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 15/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356538 | 0.83 | TERT (0.56) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL1252848 | 0.82 | KDM4E (0.64) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL29952324 | 0.82 | KDM4E (0.64) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL321127 | 0.80 | KDM4E (0.59) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL9297728 | 0.80 | TERT (0.53) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL29954415 | 0.80 | TERT (0.53) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL9297666 | 0.80 | TERT (0.53) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL22281464 | 0.77 | TERT (0.53) | TERTPOLB | |
| SCHEMBL21911967 | 0.76 | TERT (0.49) | TERTKDM4EALOX15TSHRACMSD | |
| SCHEMBL2348998 | 0.76 | TERT (0.55) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265228-A1 | Cinnamoyl compound and use of the same | NPC1, CES2, CYP51A1 | TERT 4202/4885KDM4E 2988/4885ALOX15 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.